You are using an older browser version. Please use a supported version for the best MSN experience.

Why there is opportunity in biotech and the names to watch

Kevin Mahn, Hennion and Walsh chief investment officer, joins 'The Exchange' to discuss the names he's favoring in the pharma sector.
image beaconimage beaconimage beacon